Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Sung, Anthony D  [Clear All Filters]
2023
Hussaini SMQasim, Ren Y, Racioppi A, Lew MV, Bohannon L, Johnson E, Li Y, Thompson JC, Henshall B, Darby M, et al. Financial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis. JCO Oncol Pract. 2023:OP2300243.
2022
Van Opstal J, Zhao AT, Kaplan SJ, Sung AD, Schoemans H. eHealth generated patient data in an outpatient setting after stem cell transplantation: a scoping review. Transplant Cell Ther. 2022.
Siamakpour-Reihani S, Cao F, Lyu J, Ren Y, Nixon AB, Xie J, Bush AT, Starr MD, Bain JR, Muehlbauer MJ, et al. Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia. PLoS One. 2022;17(6):e0268963.
Lew MV, Ren Y, Lowder YP, Siamakpour-Reihani S, Ramalingam S, Romero KM, Thompson JC, Bohannon LM, McIntyre J, Tang H, et al. Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplant Candidates Ages 18-80 Years. Transplant Cell Ther. 2022.
Lin C, Sajeev G, Stiff PJ, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LPiu, et al. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel Versus Umbilical Cord Blood. Transplant Cell Ther. 2022.
Lin C, DiCioccio RA, Haykal T, McManigle WC, Li Z, Anand SM, Poe JC, Bracken SJ, Jia W, Alyea EP, et al. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease: SYK Inhibition in Chronic GVHD. Transplant Cell Ther. 2022.
2021
Messina JA, Tan CYee, Ren Y, Hill L, Bush A, Lew M, Andermann T, Peled JU, Gomes A, van den Brink MRM, et al. Enterococcus Intestinal Domination is Associated with Increased Mortality in the Acute Leukemia Chemotherapy Population. Clin Infect Dis. 2021.
Smith SK, Somers TJ, Kuhn E, Laber E, Sung AD, Syrjala KL, Feger B, Kelleher SA, Majestic C, Gebert R, et al. A SMART approach to optimizing delivery of an mHealth intervention among cancer survivors with posttraumatic stress symptoms. Contemp Clin Trials. 2021:106569.
2020
Tanaka JS, Young RR, Heston SM, Jenkins K, Spees LP, Sung AD, Corbet K, Thompson JC, Bohannon L, Martin PL, et al. Anaerobic Antibiotics and the Risk of Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Smith P, Thompson JC, Perea E, Wasserman B, Bohannon L, Racioppi A, Choi T, Gasparetto C, Horwitz ME, Long G, et al. Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biol Blood Marrow Transplant. 2020.
Dandoy CE, Kim S, Chen M, Ahn KWoo, Ardura MI, Brown V, Chhabra S, Díaz MÁngel, Dvorak C, Farhadfar N, et al. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open. 2020;3(1):e1918668.
Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
2019
Cardones AR, Sullivan KM, Green C, Chao NJ, Rowe-Nichols K, Bañez LL, Burton CS, Horwitz ME, Long GD, Rao CL, et al. Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. JAMA Dermatol. 2019.
2013
Rein LAm, Sung AD, Rizzieri DA. New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation. Int J Hematol Oncol. 2013;2(1).